- Home
- POAI vs MBRX Comparison
POAI vs MBRX Comparison
Compare POAI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- MBRX
- Stock Information
- Founded
- POAI 2002
- MBRX 2015
- Country
- POAI United States
- MBRX United States
- Employees
- POAI N/A
- MBRX N/A
- Industry
- POAI Industrial Specialties
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- MBRX Health Care
- Exchange
- POAI Nasdaq
- MBRX Nasdaq
- Market Cap
- POAI 4.9M
- MBRX 5.7M
- IPO Year
- POAI N/A
- MBRX 2016
- Fundamental
- Price
- POAI $1.21
- MBRX $1.88
- Analyst Decision
- POAI Hold
- MBRX Strong Buy
- Analyst Count
- POAI 1
- MBRX 2
- Target Price
- POAI N/A
- MBRX $24.00
- AVG Volume (30 Days)
- POAI 3.4M
- MBRX 62.3K
- Earning Date
- POAI 11-12-2024
- MBRX 11-08-2024
- Dividend Yield
- POAI N/A
- MBRX N/A
- EPS Growth
- POAI N/A
- MBRX N/A
- EPS
- POAI N/A
- MBRX N/A
- Revenue
- POAI $1,484,223.00
- MBRX N/A
- Revenue This Year
- POAI N/A
- MBRX N/A
- Revenue Next Year
- POAI $569.48
- MBRX N/A
- P/E Ratio
- POAI N/A
- MBRX N/A
- Revenue Growth
- POAI N/A
- MBRX N/A
- 52 Week Low
- POAI $0.55
- MBRX $0.40
- 52 Week High
- POAI $3.76
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- POAI 54.24
- MBRX 47.84
- Support Level
- POAI $1.16
- MBRX $1.65
- Resistance Level
- POAI $1.42
- MBRX $1.99
- Average True Range (ATR)
- POAI 0.36
- MBRX 0.20
- MACD
- POAI -0.00
- MBRX 0.04
- Stochastic Oscillator
- POAI 19.21
- MBRX 71.79
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.